Immatics Biotechnologies, a biopharmaceutical company focused on cancer immunotherapy, has appointed Katina Dorton as CFO. “Dorton’s experience working with innovative life sciences companies and strong track record leading corporate transactions and managing financial operations makes her an excellent addition to the Immatics senior management team,” commented Immatics Chairman Peter Chambré.
Dorton has been a board member of US Ecology since 2014. She was a Partner at CoRise Co, a merchant banking and investment banking advisory firm, from 2010 to 2014. Previously, she was Managing Director at Needham & Company and Managing Director at Morgan Stanley. Her deep expertise in corporate finance, capital raising and M&A, having led the execution of over 60 completed financing transactions raising more than USD50 billion in equity and debt.streaming Kong: Skull Island
Immatics was founded in Tuebingen, Germany in 2000.The firm’s target discovery platform XPRESIDENT® enables the company to discover novel and highly specific cancer antigens. In August 2015, Immatics and the University of Texas MD Anderson Cancer Centre launched Immatics US in Houston, Texas, to develop multiple T-cell and TCR-based adoptive cellular therapies with over USD60 million in total funding. Dorton’s appointment following the establishing of a US presence, perhaps the greatest signal of the company’s intention to pursue a US listed IPO.